US Patent Issued to UCB BIOPHARMA on March 4 for "Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect" (British Inventors)

ALEXANDRIA, Va., March 5 -- United States Patent no. 12,240,896, issued on March 4, was assigned to UCB BIOPHARMA SRL (Brussels).

"Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect" was invented by Gareth Charles Glyndwr Davies (Slough, Great Britain) and Scott John Roberts (Slough, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or pr...